Publications by authors named "Sara Tolaney"

Claim this Profile
R
Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast Cancer.
Hope S Rugo, Virginia Kaklamani, Heather McArthur, Seth A Wander, William Gradishar, Sara M Tolaney

Clin Cancer Res· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of patients with de novo oligometastatic breast cancer treated with curative intent at a single institution.
Emily L Chen, Hillary Heiling, Tianyu Li, Jennifer R Bellon, Faina Nakhlis, Sara M Tolaney

Breast Cancer Res Treat· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of heterogeneous resistance mechanisms to tyrosine kinase inhibitors from cell-free DNA.
Heather A Parsons, Conor Messer, Katheryn Santos, Jakob Weiss, David Merrell, Sara M Tolaney

Cell Genom· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatment.
Alfred Zippelius, Sara M Tolaney, Paolo Tarantino, Joseph P Balthasar, Greg M Thurber

Nat Rev Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase Ib study of sapacitabine and olaparib in patients with BRCA1/2-mutated metastatic breast cancer.
Filipa Lynce, Noah Graham, Bose S Kochupurakkal, Huy Nguyen, Brittany Bychkovsky, Sara M Tolaney

Clin Cancer Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer.
Amin H Nassar, Elias Bou Farhat, Hassan Abushukair, Michel Alchoueriy, Samer Salem, Sara M Tolaney

J Natl Cancer Inst· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the accuracy of inflammatory breast cancer self-reported diagnoses through the metastatic breast cancer project from the count me in initiative database.
Pietro De Placido, Elizabeth Troll, Samuel M Niman, Sean Ryan, Ginny Mason, Sara M Tolaney

Breast Cancer Res Treat· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer.
Paolo Tarantino, Do Lee, Julia Foldi, Pamela R Soulos, Cary P Gross, Sara M Tolaney

J Natl Cancer Inst· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating Tumor Cell Dynamics after CDK4/6 Inhibitor for Hormone Receptor-Positive Metastatic Breast Cancer: A Biomarker Analysis from the PACE Phase II Study.
Lorenzo Gerratana, Carolina Reduzzi, Yue Ren, Rinath Jeselsohn, Reshma L Mahtani, Sara M Tolaney

Clin Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical perspective on management of key adverse events with sacituzumab govitecan.
Sara M Tolaney, Guru P Sonpavde, Paolo Tarantino, Maryam B Lustberg, Hope S Rugo

Oncologist· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer.
Javier Cortés, Kevin Punie, Carlos Barrios, Sara A Hurvitz, Andreas Schneeweiss, Sara M Tolaney

N Engl J Med· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial.
Adrienne G Waks, Jingxin Fu, Xiangying Chu, Busem Binboga Kurt, Tianyu Li, Sara M Tolaney

Nat Commun· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cellular reprogramming during anti-PD-1 and chemotherapy treatment in early-stage primary hormone receptor-positive breast cancer.
Jingxin Fu, Adrienne G Waks, Erica Pimenta, Breanna Titchen, Kevin Bi, Sara M Tolaney

Nat Commun· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Artificial intelligence as treatment support in breast cancer: current perspectives.
Stefan Lukac, Florian Putz, Giacomo De Micheli, Chiara Corti, Wolfgang Janni, Sara M Tolaney

Breast· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.
Sara M Tolaney, Zefei Jiang, Qingyuan Zhang, Romualdo Barroso-Sousa, Yeon Hee Park

N Engl J Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Timing of Recurrence after Neoadjuvant Chemo-Immunotherapy in Patients with Early-Stage Triple-Negative Breast Cancer.
Luca Licata, Marco Mariani, Giulia Viale, Rebecca Dent, Sara M Tolaney

Clin Cancer Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunoprofiling at an Institutional Scale Reveals That High Numbers of Intratumoral CD8 and PD-1 Cells Predict Superior Patient Survival Across Major Cancer Types Independent of Major Risk Factors.
Joao V Alessi, James R Lindsay, Anita Giobbie-Hurder, Bijaya Sharma, Kristen Felt, Sara M Tolaney

JCO Precis Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
APOE+ Tumor-Associated Macrophages and CD4-DOCK4 T Cells Reveal Distinct Microenvironmental Features in HER2-Low and HER2-0 Hormone Receptor-Positive Breast Cancer.
Carlos Wagner S Wanderley, Daniel E Michaud, Kenichi Shimada, Adam Nelson, Jingxin Fu, Sara M Tolaney

bioRxiv· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II study.
Kristina Fanucci, Eren D Yeh, Ruichao Shi, Lei Qin, Camden P Bay, Sara M Tolaney

Breast Cancer Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis.
Guillermo Villacampa, Tomás Pascual, Paolo Tarantino, Javier Cortés, José Perez-García, Sara M Tolaney

Lancet Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan.
Hope Rugo, Aditya Bardia, Debora S Bruno, Vinicius Ernani, Erika Hamilton, Sara Tolaney

Support Care Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The association between young age at metastatic breast cancer diagnosis and overall survival in the EMBRACE study.
Kristen D Brantley, Gregory J Kirkner, Melissa E Hughes, Leticia Varella, Georgia Suggs, Sara M Tolaney

NPJ Breast Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast Cancer.
Frederick M Howard, James Dolezal, Hanna Hieromnimon, Sara Venters, Sara Kochanny, Sara M Tolaney

medRxiv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody-drug conjugates for treating early-stage breast cancer: current use, anticipated evolutions.
Pooja Patel, Antonio Giordano, Sara Giordano, Ilana Schlam, Sara M Tolaney

NPJ Breast Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing.
Chiara Corti, Hope S Rugo, Sara M Tolaney

Am Soc Clin Oncol Educ Book· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis